CK Life Sciences Int'l. (Holdings) Inc
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; m… Read more
CK Life Sciences Int'l. (Holdings) Inc (LSI) - Total Assets
Latest total assets as of June 2025: €11.29 Billion EUR
Based on the latest financial reports, CK Life Sciences Int'l. (Holdings) Inc (LSI) holds total assets worth €11.29 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CK Life Sciences Int'l. (Holdings) Inc - Total Assets Trend (2013–2024)
This chart illustrates how CK Life Sciences Int'l. (Holdings) Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CK Life Sciences Int'l. (Holdings) Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
CK Life Sciences Int'l. (Holdings) Inc's total assets of €11.29 Billion consist of 27.5% current assets and 72.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.1% |
| Accounts Receivable | €904.81 Million | 8.4% |
| Inventory | €1.16 Billion | 10.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €714.84 Million | 6.6% |
| Goodwill | €2.70 Billion | 25.1% |
Asset Composition Trend (2013–2024)
This chart illustrates how CK Life Sciences Int'l. (Holdings) Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CK Life Sciences Int'l. (Holdings) Inc's current assets represent 27.5% of total assets in 2024, a decrease from 28.3% in 2013.
- Cash Position: Cash and equivalents constituted 5.1% of total assets in 2024, down from 7.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, a decrease from 34.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 25.1% of total assets.
CK Life Sciences Int'l. (Holdings) Inc Competitors by Total Assets
Key competitors of CK Life Sciences Int'l. (Holdings) Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
CK Life Sciences Int'l. (Holdings) Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - CK Life Sciences Int'l. (Holdings) Inc generates 0.51x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - CK Life Sciences Int'l. (Holdings) Inc is currently not profitable relative to its asset base.
CK Life Sciences Int'l. (Holdings) Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.49 | 0.97 | 0.73 |
| Quick Ratio | 0.88 | 0.56 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.03 Billion | € -76.83 Million | € -1.12 Billion |
CK Life Sciences Int'l. (Holdings) Inc - Advanced Valuation Insights
This section examines the relationship between CK Life Sciences Int'l. (Holdings) Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -4.1% |
| Total Assets | €10.79 Billion |
| Market Capitalization | $213.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values CK Life Sciences Int'l. (Holdings) Inc's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: CK Life Sciences Int'l. (Holdings) Inc's assets decreased by 4.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for CK Life Sciences Int'l. (Holdings) Inc (2013–2024)
The table below shows the annual total assets of CK Life Sciences Int'l. (Holdings) Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €10.79 Billion | -4.08% |
| 2023-12-31 | €11.25 Billion | -0.17% |
| 2022-12-31 | €11.27 Billion | -3.96% |
| 2021-12-31 | €11.73 Billion | -2.06% |
| 2020-12-31 | €11.98 Billion | +11.79% |
| 2019-12-31 | €10.71 Billion | +2.65% |
| 2018-12-31 | €10.44 Billion | -1.37% |
| 2017-12-31 | €10.58 Billion | +10.99% |
| 2016-12-31 | €9.54 Billion | +0.24% |
| 2015-12-31 | €9.51 Billion | -7.62% |
| 2014-12-31 | €10.30 Billion | +0.76% |
| 2013-12-31 | €10.22 Billion | -- |